United Therapeutics reports Q3 EPS $5.38, consensus $5.08

Reports Q3 revenue $609.4M, consensus $587.9M. “It’s a testament to our innovative research and commercial execution that we are again reporting record quarterly revenue and double-digit revenue growth,” said Martine Rothblatt, Chairperson and CEO. “On top of our record results, we continue to progress our near-term pipeline with the ongoing TETON 1 and TETON 2 studies of nebulized Tyvaso in idiopathic pulmonary fibrosis and the ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension, both of which could generate data in 2025. “With over $600M in quarterly revenue, we’re well on our way to achieving our expected $4B annual run rate by mid-decade,” said Michael Benkowitz, President and COO. “Our commercial teams achieved meaningful growth in all of our key products, and our recent field force expansion in PH-ILD will help us build on this momentum.”